Humira Approved for use in Crohn’s Disease

Humira (adalimumab), a drug previously approved to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has now been approved by the FDA for use in moderate to severe Crohn’s disease. Humira is a monoclonal antibody that works to reduce human tumor necrosis factor (TNF) alpha in the body. TNF has been found in elevated levels in people with Crohn’s disease, and it is believed to be responsible for inflammation. Humira is administered every other week by injection. The most serious side effects associated with Humira include infections and the development of lymphoma. Other side effects include upper respiratory infections, sinusitis, and nausea.

Learn more about upcoming therapies for IBD: Inflammatory Bowel Disease Drug Pipeline

Source: HUMIRA® (adalimumab) Receives FDA Approval for Treatment of Crohn's Disease. Abbott Laboratories. February 27, 2007.